Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001104659-24-109524
Filing Date
2024-10-17
Accepted
2024-10-17 16:01:56
Documents
1
Period of Report
2024-10-16

Document Format Files

Seq Description Document Type Size
1 OWNERSHIP DOCUMENT tm2426349-4_4seq1.html 4  
1 OWNERSHIP DOCUMENT tm2426349-4_4seq1.xml 4 3531
  Complete submission text file 0001104659-24-109524.txt   5334
Mailing Address 480 ARSENAL WAY SUITE 130 WATERTOWN MA 02472
Business Address 480 ARSENAL WAY SUITE 130 WATERTOWN MA 02472 781-577-5300
Eloxx Pharmaceuticals, Inc. (Issuer) CIK: 0001035354 (see all company filings)

EIN.: 841368850 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address C/O ELOXX PHARMACEUTICALS, INC. 480 ARSENAL WAY WATERTOWN MA 02472
Business Address
Androski Lindsay (Reporting) CIK: 0001936604 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-31326 | Film No.: 241377590